Our Innovation

We've focused on a new target, a proven drug and an innovative approach for drug delivery

The Right Target

An ion channel that controls the core features of disease in airway cells

TMEM16 is an ion channel expressed on airway smooth muscle and airway epithelial cells and genetic and pharmacological studies have validated its role in disease.  When activated, TMEM16 causes excessive calcium signaling that promotes inflammation and the primary sources of obstruction: namely smooth muscle tightening and too much mucus.

Learn
More

The Right Molecule

Niclosamide is a proven drug that inhibits TMEM16 calcium signaling

Niclosamide has been used safely for years to treat illness in the gut. The new science that we're following points to enormous potential to treat obstructive lung disease by blocking our ion channel target. Importantly, structural and electrophysiology studies have confirmed target binding and inhibition of TMEM 16 function.

The Right Molecule

Niclosamide is a proven drug that inhibits TMEM16 calcium signaling

Niclosamide has been used safely for years to treat illness in the gut. The new science that we're following points to enormous potential to treat obstructive lung disease by blocking our ion channel target.

Learn
More

The Right Particle

Our engineered drug particles deliver drug to the site of disease - only where it's needed and not where it isn't needed.

Supercritical Precipitation (SCP) is a best-in-class technology for generating small particle dry powder formulation. When combined with a proven and easy-to-use delivery technology this will create airborne particles that flow via inhalation to reach the target in the lungs and provide maximum efficacy.

Learn
More